P-糖蛋白在神经退行性疾病中的作用

摘要/Abstract

摘要： 神经退行性疾病(neurodegenerative disease)是一种以神经元退行性病变为基础的慢性进行性神经系统疾病,发病机制尚不明了,但一些内源性和外源性物质在脑部的异常聚集和沉积与其病因密切相关,且其往往是P-糖蛋白的底物。近年来研究表明血脑屏障的P-糖蛋白在一些神经退行性疾病发展过程中表达会减少,这可能导致致病性内外源性物质的进一步聚集和沉积,恶化病情。本文对近年来有关P-糖蛋白在神经退行性疾病的发病和病情进展中的作用作一综述。

关键词: P-糖蛋白, 神经退行性疾病, 阿尔茨海默病, 帕金森病

Abstract: Neurodegenerative disease is a form of chronic progressive neurological disease based on neuronal degeneration, and its pathogenesis is not clear, but the abnormal aggregation and deposition of some exogenous and endogenous substances are closely related to its cause, and it is usually the P-glycoprotein substrate. In recent years, studies have shown that the expression of P-glycoprotein on blood-brain barrier will be reduced in some neurodegenerative disease, which may lead to further aggregation and sedimentation of pathogenic exogenous and endogenous to deteriorate the condition. In this paper, the role played by the P-glycoprotein in the pathogenesis of neurodegenerative disease and disease progression is reviewed

Key words: P-glycoprotein, Neurodegenerative disease, Alzheimer's disease, Parkinson's disease

中图分类号:

R741

张觅, 张啟智, 楼江, 曾含清, 彭文兴. P-糖蛋白在神经退行性疾病中的作用[J]. 中国临床药理学与治疗学, 2012, 17(7): 835-840.

ZHANG Mi, ZHANG Qi-zhi, LOU Jiang, ZENG Han-qing, PENG Wen-xing. Role of P-glycoprotein in neurodegenerative disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 835-840.

参考文献

[1] Gottesman MM. Mechanisms of cancer drug resistance[J]. Annu Rev Med,2002,53:615-627.
[2] Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer[J]. Nat Rev Drug Discov,2006,5(3):219-234.
[3] 王晔,顾振纶,秦正红.蛋白质错误折叠与神经退行性疾病[J].中国临床神经科学,2005,13(4):422-426.
[4] Brown TP, Rumsby PC, Capleton AC, et al. Pesticides and Parkinson's disease-is there a link[J]. Environ Health Perspect,2006,114(2):156-164.
[5] Lam FC, Liu R, Lu P, et al.β-Amyloid efflux mediated by P-glycoprotein[J]. J Neurochem, 2001,76(4):1121-1128.
[6] Sreeramulu K, Liu R, Sharom FJ. Interaction of insecticides with mammalian P-glycoprotein and their effects on its transport function[J]. Biochim Biophys Acta, 2007,1768(7):1750-1757.
[7] Vogelgesang S, Warzok RW, Cascorbi I, et al. The role of P-glycoprotein in cerebral amyloid angiopathy: Implications for the early pathogenesis of Alzheimer's disease[J]. Curr Alzheimer Res,2004,1(2):121-125.
[8] Bartels AL, Willemsen AT, Kortekaas R, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA[J]. J Neural Transm ,2008,115(7):1001-1009.
[9] Zolokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration[J].Trends Neurosci, 2005,28(4):202-208.
[10] Selkoe DJ. Alzheimer's disease:mechanistic understanding predicts novel therapies[J].Ann Intern Med,2004,140(8):627-638.
[11] Skovronsky DM, Lee VM, Trojanowski JQ. Neurodegenerative diseases new concepts of pathogenesis and their therapeutic implications[J].Annu Rev Pathol,2006,1:151-170.
[12] Kuhnke D, Jedlitschky G, Grube M, et al.MDR1-P-Glycoprotein(ABCB1) Mediates Transport of Alzheimer's Amyloid-β Peptides-Implications for the Mechanisms of Aβ Clearance at the Blood-Brain Barrier[J]. Brain Pathol,2007,17(4):347-353.
[13] Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis of the amyloid-β peptide in a blood-brain barrier in vitro model[J]. Neurobiol Dis,2008,30(1):94-102
[14] Cirrito JR, Deane R, Fagan AM, et al. P-Glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model[J]. J Clin Invest,2005,115(11):3285-3290.
[15] Hartz AMS, Miller DS,Bauer B. Restoreing blood-brain barrier P-glycoprotein reduces brain amyloid-β in a mouse model of Alzheimer's disease[J]. Mol Pharmacol,2010,77(5):715-723.
[16] Abuznait AH, Cain C, Ingram D, et al. Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid:investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease[J].J Pharm Pharmacol,2011,63(8):1111-1118.
[17] Brenn A, Grube M,Peters M, et al. Beta-amyloid downregulates MDR1-P-Glycoprotein(ABCB1) expression at the blood-brain barrier in mice[J]. Int J Alzheimers Dis, 2011,2011: 690121.
[18] Toornvliet R, van Berckel BN, Luutrsema G, et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C] verapamil and positron emission tomography[J]. Clin Pharmacol Ther ,2006,79(6): 540-548.
[19] Loeb MB, Molloy DW, Smieja M, et al. A randomized ,controlled trial of doxycycline and rifampin for patients with Alzheimer's disease[J].J Am Geriatr Soc ,2004,52(3):381-387.
[20] Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer's disease[J]. Eur J Neurol,2002,9(4):377-382.
[21] Hussain I, Hawkins J, Harrison D, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo[J]. J Neurochem,2007,100(3):802-809.
[22] Dinis-Oliveira RJ, Remiao F, Duarte JA, et al. P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity[J]. Free Radic Biol Med,2006,41(8):1213-1224.
[23] Schinkel AH, Smit AM, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs[J].Cell,1994,77(4):491-502.
[24] Shabbir A, DiStasio S, Zhao J, et al. Differential effects of the organochlorine pesticide DDT and its metabolite p,p'-DDE on p-glycoprotein activity and expression[J]. Toxicol Appl Pharmacol ,2005,203(2):91-98.
[25] Westerlund M, Belin AC, Olson L, et al. Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients[J].Cell Tissue Res,2008,334(2):179-185.
[26] Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo[J]. Ann Neurol,2005,57(2):176-179.
[27] Tan EK, Khjavi M, Thornby JI, et al. Variability and validity of polymorphism association studies in Parkinson's disease[J].Neurology,2000,55(4):533-538.
[28] Tan EK, Chan DK, Ng PW, et al. Effect of MDR1 haplotype on risk of Parkinson's disease[J]. Arch Neurol,2005,62(3):460-464.
[29] Lee CG, Tang K, Cheung YB, et al.MDR1,the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese[J]. J Med Genet,2004,41(5):e60.
[30] Westerlund M, Belin AC, Anvret A, et al. Association of a polymorphism in the ABCB1 gene with Parkinson's disease[J]. Parkinsonism Relat Disord,2009,15(6):422-424.
[31] Dutheil F, Beaune P, Tzourio C, et al. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease[J]. Arch Neurol,2010,67(6):739-745.
[32] Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease[J]. Pharmacogenetics, 2002, 12(7):529-534.
[33] Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease[J]. Pharmacogenetics, 2003,13(5):259-263.
[34] Zschiedrich K, König IR,Brüggemann N,et al. MDR1 variants and risk of Parkinson disease Association with pesticide exposure[J]. J Neurol,2009,256(1):115-120.
[35] Funke C,Soehn AS,Tomiuk J,et al. Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients[J]. J Neural Transm ,2009,116(4):443-450.
[36] Vogelgesang S, Glatzel M, Walker LC, et al. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease[J]. Acta Neuropathol,2006,111(5):436-443.
[37] Milane A,Fernandez C,Vautier S,et al. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier[J].J Neurochem,2007,103(1):164-173.